M. Lee

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens

L. Gong, T. Klein, D. Nelson, 2014, Clinical pharmacology and therapy.

Validating and automating learning of cardiometabolic polygenic risk scores from direct-to-consumer genetic and phenotypic data: implications for scaling precision health research

N. Katsanis, A. Ioannidis, M. Vernekar, 2022, medRxiv.

Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen‐B Genotype and Allopurinol Dosing

C. Thorn, T. Klein, C. Thorn, 2013, Clinical pharmacology and therapeutics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing

T E Klein, M. Whirl‐Carrillo, T. Klein, 2014 .

Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta‐Analysis

Mohamed H. Shahin, R. Altman, B. Horne, 2012, Clinical pharmacology and therapeutics.

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

M. Whirl‐Carrillo, L. Gong, R. Altman, 2011, Clinical pharmacology and therapeutics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens

L. Gong, T. Klein, D. Nelson, 2014, Clinical pharmacology and therapeutics.